EBMT NEWSLETTER | January 2016 | Volume 50 - Issue 1

EBMT
Important dates
Content:
Resistance Pattern of Gram-negative Bacteria Isolated from Blood from HSCT Recipients
Allogeneic SCT for patients with acquired Pure Red Cell Aplasia
HSCT for adults with Fanconi Anaemia
Incidence of Autoimmune Cytopenias after allogeneic HSCT for Severe Aplastic Anaemia
Feasibility survey on the use of biosimilars in healthy donors


Resistance Pattern of Gram-negative Bacteria Isolated from Blood from HSCT Recipients

A non-interventional prospective multicentre study by the IDWP to determine the incidence and pattern of antimicrobials resistance among Gram-negative bacteria isolated from blood in HSCT patients during the first 6 months after the transplantation.

Please submit your last episodes and please make sure your patients are registered in the EBMT registry
 
All participating centres should submit their cases of gram-negative bacteremia for all patients transplanted before 25 May 2015.
Patients transplanted until May 25th will have to have been followed for 6 months to see if they develop a case (meaning the latest episodes until November 25th, 2015).
 
The study has closed on November 25th, 2015.
  • Episodes for consecutive patients in the study period (=since you started including patients and until 25 May 2015) not yet registered with the Data Office need to be submitted as soon as possible!!
  • A minimum of Med A for your patients with episodes during the study period will need to be entered in the EBMT registry as soon as possible!!
We are happy to inform you that over 650 episodes have already been reported to us.

The IDWP thanks all participating centres for the wonderful effort they have put in!
 
When you have any questions or concerns, please contact Jennifer Hoek of the EBMT Data Office via idwpebmt@lumc.nl 

Allogeneic SCT for patients with acquired Pure Red Cell Aplasia

A study by the SAAWP

Call for patient data!
 
Patients are eligible for this study if they were diagnosed with acquired Pure Red Cell Aplasia (aPRCA) and received an allogeneic transplant for this disease between 2000 and 2013. Centres with such a patient registered in the EBMT database have been contacted to participate in this study and received a prefilled MED-B/C patient form. We very much hope you want to contribute to this unique study and return the completed patient forms.
 
For more information on this study or to obtain the (prefilled) patient form, please contact Cora Knol of the EBMT Data Office via saawpebmt@lumc.nl.

HSCT for adults with Fanconi Anaemia

A study by the SAAWP

Call for MED-B/C forms! Deadline to send in data: January 31st, 2016.
 
Eligibility criteria for this study are: patients diagnosed with Fanconi Anaemia who received an allogeneic transplant at age >=18 in the years 1990-2014. Centres with (potential) eligible patients were identified based on information in the EMBT registry database. Those centres received an invitation containing a prefilled restricted MED-B/C form. Thus far we received completed forms of about half of the eligible patients. If you have eligible patients and have not contributed yet, we hope you still want to participate and send in the completed MED-B/C form before January 31st, 2016.
 
For more information on this study or to obtain the (prefilled) patient form, please contact Cora Knol of the EBMT Data Office via saawpebmt@lumc.nl.

Incidence of Autoimmune Cytopenias after allogeneic HSCT for Severe Aplastic Anaemia

A study by the SAAWP

Call for centre and patient registration!

We are looking for patients receiving a first allogeneic HSCT for aplastic anaemia in the years 2002-2012. Among these patients we want to define the incidence of Autoimmune Cytopenia after allograft. For patients developing Autoimmune Cytopenia we will request to complete a restricted MED-B/C form in a later stage of this study. If you are interested to participate in this study, we would be very much pleased if you could complete the survey using the following link: https://www.surveymonkey.com/r/HT9MBB7.
 
For more information on this study, please contact Cora Knol of the EBMT Data Office via saawpebmt@lumc.nl

Feasibility survey on the use of biosimilars in healthy donors

*** survey ***

 This survey also contains a question regarding autologous settings
  
EBMT has implemented a platform for a Donor Outcome Registry in the EBMT ProMISe database. There are, at this moment, several proposals that could support EBMT in setting up this important initiative.
Therefore we want to ask you to please complete a few questions in the Donor Outcome Registry Survey that will help us assess the feasibility of the different projects as well as estimate the general interest in completion of the donor registry.
 
The link below will take you to the survey. 
https://www.surveymonkey.com/r/donorregistry
 
The survey consists of three parts. It starts with general questions on products used for mobilisation in healthy donors, followed by questions specific to the biosimilars Accofil and Nivestim. The survey ends with a few more general questions. Parts of the survey may be skipped when questions are irrelevant to your situation.
 
We would appreciate to receive your response at your earliest convenience.
Should you have any questions or concerns, please do not hesitate to contact us via cmwpebmt@lumc.nl 
 
Sincerely,
 
Jörg Halter - Chair Donor Outcomes Committee   
Nicolaus Kröger - Chair Scientific Council         
Anna Sureda - Secretary Executive Committee
EBMT Data Office Leiden

 
Bookmark and Share